Comparing Quality of Life in Chronic Dermatological Diseases: Pyoderma Gangrenosum, Hidradenitis Suppurativa, and Venous Ulcers

Introduction: Chronic dermatological diseases, including Hidradenitis Suppurativa (HS), Pyoderma Gangrenosum (PG), and Venous Ulcers (VU), significantly affect health-related quality of life (HRQoL). These conditions impose physical, psychological, and social burdens that vary in severity. This study compares HRQoL across these three diseases using the Dermatology Life Quality Index (DLQI). Methods: This study evaluated a cohort of 45 patients, comprising 15 with HS (Hurley stage II and III), 15 with PG (including post-surgical cas- es), and 15 with VU. HRQoL was assessed using the DLQI, a validated tool designed to quantify the impact of dermatological conditions on patients’ daily lives. The analysis was conducted at the time of diagnosis, prior to the initiation of any therapeutic interventions. Statistical analyses were performed to compare mean DLQI scores, assess intergroup variability, and identify significant differences across the three conditions. Results: The DLQI scores showed that PG had the highest impact on HRQoL, with an average score of 25 (range 8–30). This reflects the chronic and recurrent nature of the disease, although post-surgical cases, which had less pain, slightly lowered the average. HS had a mean score of 20 (range 16–27), indicating significant impairment due to pain, draining lesions, and psychosocial challenges. VU had a mean score of 15 (range 7–25), showing moderate impact, though severe cases still faced signifi- cant burdens. Discussion: This study highlights severe HRQoL impairment in PG and HS compared to VU. The inclusion of post-surgical PG cases and ad- vanced HS stages demonstrates the need to tailor HRQoL evaluations to specific patient populations. Multidisciplinary care strategies focusing on both physical and psychological challenges are critical, especially for PG and HS. Future research should develop condition-specific tools to better measure HRQoL and explore treatments that reduce disease burden and improve patient outcomes. CS-027 (RPT-005) ON101 Significantly Enhances Healing and Reduces Amputation Rates in Infected Diabetic Foot Ulcers (DFUs) Zoe Chen, MD Introduction: Infection is a leading contributor to high amputation rates among diabetic foot ulcer (DFU) patients. Standard care for infected DFUs typically includes systemic antibiotics and silver-im- pregnated dressings, but clinical outcomes remain suboptimal, with published wound closure rates of only 27.5% at 6 months and 44.5% at 12 months. Modulating macrophage-driven immune responses within the infected wound microenvironment has emerged as a promising strategy to enhance healing. This study evaluates the efficacy of ON101, a topical macrophage modulator, used alongside systemic antibiotics in managing infected DFUs. Methods: Retrospective data were collected from 178 patients with Wagner 2 to 4 DFUs who received standard hospitalized care, including pressure relief and adjuvant therapies such as negative pressure wound therapy, dermal regeneration templates, skin grafts/flaps, partial amputa- tions, and silver foam dressings, to reduce ulcer severity. Following this downgrading phase, 88 patients with active infection DFUs (IDSA grade 2/3) receiving systemic antibiotic, 62 patients were treated with ON101 monotherapy and 26 continued with adjuvant therapies. The incidence of wound closure in 90 days, 120 days and 150 days and mean healing time were assessed. Amputation incidence in one year post-downgrading phase was also followed up. Results: The ON101 group significantly increased healing vs. the control group: at 90 days: 62.9% vs. 11.5% , p < 0.0001; at 120 days: 75.8% vs. 23.1% , p < 0.0001; and at 150 days: 85.5% vs. 46.2% , p = 0.00013. Ad- ditionally, the mean healing time was significantly shorter in the ON101 group (94.5 days) compared to the control group (144.5 days, p < 0.0001). Among the IDSA 2/3 patients, the amputation rate within 1 year after the downgrading process showed that the amputation incidence occurred in ON101 group versus the control was 3.2% (2/62) vs. 19.2% (5/26), with p = 0.011. Notably, for those who healed within 120 days, the amputation rates were 0% vs. 16.7% , with p = 0.0047. Discussion: ON101 significantly enhances wound closure and reduces healing time in infected DFUs. At 90 days, ON101 achieved a five-fold increase in wound closure compared to the control, demonstrating its potential as an early intervention during infection control to deliver faster and more favorable outcomes. These results highlight the critical role of macrophage modulation in repairing tissue damage and promoting healing within infected wound environments. ON101 offers a compelling therapeutic advantage in managing infected DFUs and reducing the risk of limb loss.